Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC
Executive Summary
Spectrum is expanding a clinical trial with its novel, oral pan-HER inhibitor poziotinib into the first-line treatment of NSCLC with EGFR or HER2 exon 20 insertion mutations, which could provide a much-needed new option for these patients. The move also marks further positive development progress for the drug, which the US firm licensed in from Hanmi.
You may also be interested in...
Spectrum Reshuffles Focus, Selling Seven Products To Aurobindo
By selling seven approved oncology/hematology products to a US affiliate of Aurobindo, Spectrum gets cash to increase focus on late-stage candidates Rolontis for neutropenia and poziotinib for solid tumors.
Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC
Hanmi and Spectrum's novel oral pan-HER inhibitor poziotinib shows promising interim results in Phase II study in NSCLC patients with EGFR exon 20 insertion mutations, an unmet need.